07:14 AM EDT, 10/20/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported a Q3 non-GAAP net loss Monday of $0.13 per diluted share, widening from a loss of $0.05 a year earlier.

Analysts polled by FactSet expected a loss of $0.18.

The biopharmaceutical start-up reported no revenue.

The company reported cash and cash equivalents, as well as short-term investments, of $238.6 million as of September 30, down from $412.3 million as of December 31.

Shares of the company were down 5.5% in recent premarket activity.